Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxoSmithKline Plc receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan (albiglutide)


Wednesday, 26 Mar 2014 09:07am EDT 

GlaxoSmithKline Plc:European Commission granted marketing authorisation for once-weekly diabetes treatment Eperzan.Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control. 

Company Quote

45.65
0.29 +0.64%
24 Oct 2014